ROCHESTER, Minn. -- A Mayo Clinic case series analysis has pinpointed for the first time syndromes associated with toxic damage to the brain and nervous system from manganese fumes generated during welding. The analysis also revealed that all affected patients shared a risk factor: welding with inadequate ventilation. The findings are published online at www.neurology.org and will appear in the June 28 print issue of Neurology.
Due to ethical concerns, human trials with manganese fume exposure are not conducted. Most information about welding and health hazards is gleaned from animal studies or from analyzing patient cases in which exposure has occurred.
In the Mayo analysis, the researchers examined medical records from eight patients referred to the clinic between 1999 and 2005 for various nervous system complaints. All of their MRI scans showed an area of increased T1 signal intensity in the basal ganglia region of the brain, which appears as a bright spot on the MRI scan and is a biological indicator of manganese accumulation. All were men involved in welding for one to 25 years before symptoms developed. Initial symptoms varied, but multiple symptoms developed over time, including cognitive impairment, headaches and tremor in six of the patients, and balance problems in five patients. Each patient was diagnosed with neurotoxicity from welding fumes after undergoing testing appropriate to the patient's complaints, such as blood and urine testing, brain MRI and psychological testing of intelligence, aptitude and personality traits.
The increased T1 signal in the brains of the eight patients as revealed by MRI is an uncommon finding in brain imaging, according to Keith Josephs, M.D., Mayo Clinic neurologist who spearheaded the analysis. This is the first case series of welders with this abnormal signal highlighting such widespread neurological impairment.
"In the setting of prominent manganese exposure in the environment, as occPage: 1 2 3 Related medicine news :1
Contact: Lisa Lucier
. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer2
. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative3
. Clinical review -- A psychological approach to the management of irritable bowel syndrome4
. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 20075
. New Mayo Clinic MRI technology enables noninvasive liver diagnoses6
. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference7
. Elsevier launches the Clinics on ScienceDirect8
. Clinical guidelines for blood conservation during cardiac procedures developed9
. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 200710
. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 200711
. Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression